Vol. 6 No. 3 (2026)
Reimbursement Reviews

Tofersen (Qalsody)

decorative image of the issue cover

Published March 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Tofersen (Qalsody), 100 mg per 15 mL (6.7 mg/mL), solution for intrathecal injection.
  • Indication: Qalsody (tofersen injection) is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.